TNBC
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
TNBC
Jul 25, 2024, 08:58 |
Insight
Marleen Kok: How do we get from one-size-fits-all to personalized treatment for TNBC
Marleen Kok, Breast Medical Oncologist at the Netherlands Cancer Institute, shared on X: "Today from…
Jul 24, 2024, 00:59 |
Insight
Luca Licata: The fate of immunotherapy trials in breast cancer
Marco Mariani, Resident in Medical Oncology at San Raffaele Scientific Institute, shared a post on X…
Jul 22, 2024, 23:09 |
Blog
Aleix Prat: TNBC-DX - new genomic profiling tool for the treatment of early-stage triple-negative breast cancer (TNBC)
Aleix Prat, Director of Cancer Institute and Blood Disorders at Clinical Hospital of Barcelona, shared…
Jul 10, 2024, 05:38 |
Blog
Marleen Kok: My team will be awarded grant of 4.1 million euro from KWF Dutch Cancer Society
Marleen Kok, Associate Professor at The Netherlands Cancer Institute, shared a post on X: "Incredibly…
Jul 2, 2024, 03:02 |
Blog
Myriam Chalabi: Patients with stage 1c TNBC with high TILs have an excellent prognosis without chemo
Myriam Chalabi, Medical Oncologist and Cancer Immunotherapy researcher at Antoni van Leeuwenhoek, shared a post…
Jun 29, 2024, 03:18 |
Blog
Peter Schmid's findings on atezolizumab and sacituzumab govitecan for advanced TNBC - ESMO
ESMO shared a post on LinkedIn: “For ESMO members: Breaking Science in Breast Cancer. Peter Schmid…
Jun 27, 2024, 13:27 |
Blog
Douglas Flora: MRD AI tests are proving to be invaluable tools in our decision-making process
Douglas Flora shared a post on LinkedIn: “As I’ve been working my way through the latest…
Jun 26, 2024, 03:41 |
Insight
Paolo Tarantino: Opportunities to improve outcomes for early recurrent TNBC
Paolo Tarantino shared a post on X: . "Early recurrent TNBC (Triple-Negative…
Jun 25, 2024, 13:37 |
Insight
Sacituzumab govitecan with or without pembrolizumab in TNBC
The Dana-Farber’s Breast Oncology Center shared on X: "Dana-Farber’s Breast Oncology Center is leading a…
Jun 12, 2024, 04:23 |
Insight
Piotr Wysocki: Physicial exercise reduces the risk of recurrence - TNBC and HER2+/HR- breast cancer
Piotr Wysocki recently posted on LinkedIn: "Soldato D et al. conducted a multicenter prospective cohort analysis…
Jun 6, 2024, 02:15 |
Blog
Paolo Tarantino: Rebecca Shatsky presents the Dato/durva module of I-SPY2.2
Paolo Tarantino shared on X/Twitter: "Rebecca Shatsky presents the Dato/durva module of I-SPY2.2. Neoadjuvant Dato-DXd/durva showed…
May 26, 2024, 13:42 |
Insight
Some of the highlights while waiting for ASCO24 by Yakup Ergün
Yakup Ergün, Medical Oncologist at Ankara Numune Training and Research Hospital, shared a post on…
May 26, 2024, 06:49 |
Societies
Paolo Tarantino: Less than a week to what promises to be a terrific ASCO24
Paolo Tarantino recently shared a post on X: "Less than a week to what promises…
May 21, 2024, 15:41 |
Insight
Yakup Ergün: A valuable retrospective study on PD-L1 alteration after NAC in TNBC
Yakup Ergün, Medical Oncologist at Ankara Numune Training and Research Hospital, shared a post on…
May 18, 2024, 09:54 |
Societies
Paolo Tarantino: Why was IMpassion132 negative?
Daniel Stover, Medical Oncologist and Computational Biologist at Ohio State University Comprehensive Cancer Center, shared…
May 17, 2024, 04:08 |
Blog
Dana-Farber’s Breast Oncology Center is leading a study for metastatic triple-negative Breast Cancer
Janice Cowden shared a post by Dana-Farber’s Breast Oncology Center on X/Twitter: "If you, or someone…
May 5, 2024, 00:20 |
Blog
Margaret Gatti-Mays: Great time traveling to Cleveland Clinic to give Grand Rounds
Margaret Gatti-Mays, Associate Professor in the Division of Medical Oncology at the OSUCCC – James…
Apr 20, 2024, 20:17 |
Insight
Paolo Tarantino: Tumor-infiltrating lymphocytes (TILs): not only prognostic in Triple-Negative Breast Cancer
Paolo Tarantino, Research fellow at Dana Farber Cancer Institute, shared on X: "Tumor-infiltrating lymphocytes (TILs): not…
Apr 20, 2024, 14:18 |
Blog
Elisa Agostinetto: The proportion of patients with an actionable alteration (AA) in serial cfDNA decreases with time
Elisa Agostinetto, Clinical Research Fellow at Jules Bordet Institute in Brussels, shared a post on…
Apr 12, 2024, 05:34 |
Insight
Joe Lennerz: Quickly sharing a fantastic paper on tumour infiltrating lymphocytes in triple-negative breast cancer
Joe Lennerz, Chief Scientific Officer at BostonGene, shared on LinkedIn: "Quickly sharing a fantastic paper…
Apr 7, 2024, 11:53 |
Insight
Roberto Leon-Ferre: The role of immune activation on the prognosis of early TNBC if chemo is not given?
Roberto Leon-Ferre, Assistant Professor at Mayo Clinic, shared on X/Twitter: "What is the role of…
Apr 5, 2024, 16:38 |
Insight
Roberto Leon-Ferre: The role of immune activation on the prognosis of early TNBC if chemotherapy is not given
Roberto Leon-Ferre, Medical Oncologist at Mayo Clinic, shared on their X/Twitter: ''What is the role…
Apr 5, 2024, 08:29 |
Drugs
Piotr Wysocki: Promising activity of maintenance olaparib in advanced breast cancer patients responding to platinum-based chemotherapy
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Mar 12, 2024, 21:01 |
Blog
Rebecca Shatsky: Got to meet the fantastic Sumanta Pal in person finally, as well as his incredible fellow
Rebecca Shatsky and Sumanta Pal, Professor and Vice Chair of Academic Affairs, City of Hope…
Feb 19, 2024, 18:30 |
Insight
Erman Akkus: Advanced breast cancer in 2023
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter: "Best of the year:…
Feb 10, 2024, 08:06 |
Insight
Paolo Tarantino: Final OS from BROCADE3 phase 3 trial
Paolo Tarantino, Medical Oncologist, Research Fellow at Dana-Farber Cancer Institute, shared a post on X/Twitter: "Final…
Dec 14, 2023, 16:23 |
Insight
SABCS23 Day 1 Highlights by Oncology Brothers
Oncology Brothers have recently shared their highlights from SABCS23. Below we feature the first day's…
Dec 12, 2023, 17:44 |
Insight
Piotr Wysocki: SABCS2023 - Adjuvant chemoimmunotherapy does not benefit TNBC patients
Piotr Wysocki, Head of Department of Oncology at Jagiellonian University Hospital, shared on LinkedIn: "SABCS2023…
Dec 11, 2023, 11:27 |
Insight
Margaret Gatti-Mays: A great option for our patients with TNBC
Margaret Gatti-Mays, Associate Professor in the Division of Medical Oncology at the OSUCCC – James…
Dec 8, 2023, 17:50 |
Drugs
Pure Biologics to test molecule PBA-0405 in project PB004 in a Phase 0 clinical trial in patients with solid tumors - The Antibody Society
The Antibody Society shared on their LinkedIn page: "In an unusual (to us anyway) move,…
Sep 12, 2023, 19:57 |
Insight
Giampaolo Bianchini: Out on Nature our work ‘Spatial predictors of immunotherapy response in triple-negative breast cancer’ lead by Ali Lab and myself.
Quoting Giampaolo Bianchini, the Head of the Translational and Immunotherapy research group at the San…
Sep 11, 2023, 00:27 |
Insight
Our preclinical study evaluating the efficacy of BRD4 inhibitor+Paclitaxel+anti-PD-L1 combination for Triple negative breast cancer is out in Molecular Cancer Therapeutics today. - Polyak Lab
Sep 7, 2023, 19:49 |
Blog
Join us for one or more of the TNBC virtual meet-ups this September. - Triple Negative Breast Cancer Foundation
TNBC Foundation shared on their X/Twitter page: ''A new month brings new opportunities to connect…
Aug 19, 2023, 17:44 |
Insight
Kathryn Gallaway: Continuing our discussion on disparities in breast cancer.
Quoting Kathryn Gallaway, the Associate Medical Director of DAVA Oncology, on Twitter: "Continuing our discussion…
Aug 17, 2023, 16:07 |
Insight
Stephanie Graff: Triple-negative Breast Carcinoma With Apocrine and Histiocytoid Features.
In a recent tweet, Stephanie Graff wrote: ''Sharing our latest work! Triple-negative Breast Carcinoma With…
Jun 6, 2023, 19:11 |
Opinion
HER2-low is a dynamic, rather than static definition! - Paolo Tarantino
Retrospective HER2-low analysis of 512 patients with TNBC presented by Yale Bar. confirms high discordance…
All:
36
Posts:
1 - 100
The largest philanthropic partnership in The V Foundation’s history - Dolphins Cancer Challenge
Glecirasib: A Promising Novel KRAS G12C Inhibitor in Clinical Development
How the Médecins Sans Frontières Journal Inspired a Lifetime of Humanitarian Service: Paul Spiegel
OncoDaily Party and Yvonne Award Photos - Part 1
Michael Douglas: The Untold Story of His Battle Against Cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube